Astellas Pharma Inc. ALPMY
16.35 USD +0.35 (+2.19%)
Nov 5, 2026, 3:59 PM EST
16.35 Day range 16.82
10.91 52-week range 17.35
- YTD
- +23.02%
- 1 year
- +47.43%
- Market cap
- 29.32B
- EPS (ttm)
- 1.35
- P/E ratio
- 12.11
- YTD return
- +23.02%
- 1-year return
- +47.43%
- Volume
- 6.18K
- Avg volume
- 98.14K
- Open
- 16.44
- Previous close
- 16.00
- Day's range
- 16.35 – 16.82
- 52-week range
- 10.91 – 17.35
- Earnings date
- Oct 29, 2026
MAX +9.01 (+122.75%)
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.3912.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.3912 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3363 | 0.503 | +0.17 | +49.57% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1941 | 0.1521 | -0.04 | -21.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2916 | 0.364 | +0.07 | +24.83% |
| Oct 30, 2025 | Sep 30, 2025 | 0.1993 | 0.30 | +0.10 | +50.53% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1356 | 0.40 | +0.26 | +194.99% |
News
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? 
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year? 
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis 
Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s What Happened 
Astellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9% 
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer 
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers 
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis 
New Strong Sell Stocks for August 19th 
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
Your note
Sign in to keep a note on ALPMY — it syncs with the Stock Master app.